Join to access to all OVN content. Join for Free
Life After Medical Affairs: From MSL to M & A
St. Onge MSL to Business Development Paratek career transition overcoming glass ceiling in medical affairs LinkedIn for career advancement

Life After Medical Affairs: From MSL to M & A


Share This Article


Summary

In this episode, Steve St. Onge shares his unique journey from traditional MSL roles to business development at Paratek. He discusses his background, transition to industry, and involvement in nontraditional MSL work. Steve delves into the challenges faced during his shift to business development and highlights essential skills for success in this area. The conversation also touches on overcoming the glass ceiling in medical affairs and leveraging medical affairs expertise in business roles. Steve offers valuable advice for MSLs considering a move into M&A or business development, emphasizing the importance of company research and utilizing LinkedIn for career advancement.

This episode features Steve St. Onge, Sr Director Business Development at Paratek discusses his career path from Medical Affairs to Business Development (M and A) and how he got there
We discuss….

👉 How he transitioned from Medical Affairs to M and A
👉 What his role in Business Development and M and A entails
👉 The difference between Corporate Development and Business Development
👉 Why LinkedIn can be an MSLs worst enemy
👉 The “glass ceiling” in Medical Affairs
👉 Why you need to learn the DNA of a company

Click for Source
St. Onge, MSL to Business Development, Paratek career transition, overcoming glass ceiling in medical affairs, LinkedIn for career advancement

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN